<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187898</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-GCF-104</org_study_id>
    <nct_id>NCT04187898</nct_id>
  </id_info>
  <brief_title>Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer</brief_title>
  <official_title>Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of Eflapegrastim on duration of&#xD;
      neutropenia in patients with early-stage breast cancer when administered at varying intervals&#xD;
      following Docetaxel and Cyclophosphamide administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, open label, actively-controlled study to evaluate the same day&#xD;
      dosing of Eflapegrastim on duration of neutropenia when administered at varying intervals&#xD;
      following Docetaxel and Cyclophosphamide (TC) chemotherapy in patients with early-stage&#xD;
      breast cancer .&#xD;
&#xD;
      Approximately 45 patients will be enrolled and randomized in a 1:1:1 ratio to 3 dosing time&#xD;
      schedule arms.&#xD;
&#xD;
      Each cycle will be 21 days. Total 4 cycles will be evaluated for this study. On Day 1 of&#xD;
      Cycle 1, patients will receive Docetaxel and Cyclophosphamide (TC)chemotherapy followed by&#xD;
      administration of Eflapegrastim at 1 of 3 time schedules post-TC (30mins, 3 hours or 5&#xD;
      hours). During Cycles 2-4, patients will receive Eflapegrastim 24 hours after TC&#xD;
      administration (on Day 2).&#xD;
&#xD;
      Safety evaluations will be conducted once the first 3 patients in each arm have completed&#xD;
      Cycle 1 to determine if it is safe for patients to continue in that particular treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Grade 4 Neutropenia (DSN) in Cycle 1</measure>
    <time_frame>Cycle 1 is 21 days</time_frame>
    <description>DSN is defined as the number of days of severe neutropenia where the Absolute Neutrophil Count (ANC&lt;0.5x10^9/L) from the first occurrence of an ANC below the threshold.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutropenia in Cycle 1.</measure>
    <time_frame>Cycle 1 is 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of severe neutropenia in Cycle 1.</measure>
    <time_frame>Cycle 1 is 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 febrile neutropenia (FN) in Cycle 1</measure>
    <time_frame>Cycle 1 is 21 days</time_frame>
    <description>FN is defined as having an ANC&lt;1.0x10^9/L and either a single temperature of &gt;38.3 degrees celcius (101.0 F) or a sustained temperature of &gt;38.0 degrees celcius (100.4 F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Eflapegrastim in Cycle 1</measure>
    <time_frame>Cycle 1 is 21 days</time_frame>
    <description>Will be measured by the concentration of Eflapegrastim in plasma at various timepoints in Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutropenic complications, including hospitalization due to neutropenia, febrile neutropenia, and use of anti-infectives during Cycle 1</measure>
    <time_frame>Cycle 1 is 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events/serious adverse events as a measure of safety</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CD34+ count in the peripheral blood during Cycle 1</measure>
    <time_frame>First 10 days of Cycle 1</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Neutropenia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Eflapegrastim @ 30mins post TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).&#xD;
Supplied in prefilled single-use syringes for subcutaneous injection.&#xD;
Cycle 1: Administered on the same day as TC chemotherapy, 30 minutes from the end of TC administration.&#xD;
Cycles 2-4: Administered 24 hours after TC chemotherapy administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eflapegrastim @ 3 hours post TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).&#xD;
Supplied in prefilled single-use syringes for subcutaneous injection.&#xD;
Cycle 1: Administered on the same day as TC chemotherapy, 3 hours from the end of TC administration.&#xD;
Cycles 2-4: Administered 24 hours after TC chemotherapy administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eflapegrastim @ 5 hours post TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eflapegrastim (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF).&#xD;
Supplied in prefilled single-use syringes for subcutaneous injection.&#xD;
Cycle 1: Administered on the same day as TC chemotherapy, 5 hours from the end of TC administration.&#xD;
Cycles 2-4: Administered 24 hours after TC chemotherapy administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eflapegrastim</intervention_name>
    <description>Administered in Cycle 1, 30 minutes after TC chemotherapy.&#xD;
Administered in Cycle 2-4, on day 2 of each cycle.</description>
    <arm_group_label>Eflapegrastim @ 30mins post TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eflapegrastim</intervention_name>
    <description>Administered in Cycle 1, 3 hours after TC chemotherapy.&#xD;
Administered in Cycle 2-4, on day 2 of each cycle.</description>
    <arm_group_label>Eflapegrastim @ 3 hours post TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eflapegrastim</intervention_name>
    <description>Administered in Cycle 1, 5 hours after TC chemotherapy.&#xD;
Administered in Cycle 2-4, on day 2 of each cycle.</description>
    <arm_group_label>Eflapegrastim @ 5 hours post TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m^2 IV infusion.&#xD;
Administered on Day 1 of each cycle.</description>
    <arm_group_label>Eflapegrastim @ 3 hours post TC</arm_group_label>
    <arm_group_label>Eflapegrastim @ 30mins post TC</arm_group_label>
    <arm_group_label>Eflapegrastim @ 5 hours post TC</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m^2 IV infusion.&#xD;
Administered on Day 1 of each cycle.</description>
    <arm_group_label>Eflapegrastim @ 3 hours post TC</arm_group_label>
    <arm_group_label>Eflapegrastim @ 30mins post TC</arm_group_label>
    <arm_group_label>Eflapegrastim @ 5 hours post TC</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and capable of giving written Informed Consent and able to adhere to study&#xD;
             drug dosing time and blood draw schedules&#xD;
&#xD;
          -  New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as&#xD;
             operable Stage I to Stage IIIA breast cancer&#xD;
&#xD;
          -  Candidate to receive adjuvant or neoadjuvant TC chemotherapy&#xD;
&#xD;
          -  ANC ≥1.5×10^9/L&#xD;
&#xD;
          -  Platelet count ≥100×10^9/L.&#xD;
&#xD;
          -  Hemoglobin &gt;10 g/dL.&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 50 mL/min.&#xD;
&#xD;
          -  Total bilirubin ≤1.5 mg/dL.&#xD;
&#xD;
          -  AST/SGOT and ALT/SGPT ≤2.5×ULN. (upper limit of normal)&#xD;
&#xD;
          -  Alkaline phosphatase ≤2.0×ULN.&#xD;
&#xD;
          -  ECOG ≤2&#xD;
&#xD;
          -  Willing to practice 2 forms of contraceptives (1 must be a barrier method), from study&#xD;
             entry through 30 days after last dose of study drug/ early discontinuation&#xD;
&#xD;
          -  Negative urine pregnancy test within 30 days before randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of&#xD;
             the cervix) or life-threatening disease&#xD;
&#xD;
          -  Known sensitivity to E. coli derived products&#xD;
&#xD;
          -  Concurrent adjuvant cancer therapy other than the trial-specified therapies&#xD;
&#xD;
          -  Locally recurrent/metastatic breast cancer&#xD;
&#xD;
          -  Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical&#xD;
             development within 3 months prior to the administration of study drug&#xD;
&#xD;
          -  Receiving anti-infectives, has an underlying medical condition or other serious&#xD;
             illness that would impair the ability to receive protocol-specified treatment&#xD;
&#xD;
          -  Used any investigational drugs, biologics, or devices within 30 days prior to study&#xD;
             treatment or plans to use any of these during the course of the study&#xD;
&#xD;
          -  Prior bone marrow or stem cell transplant&#xD;
&#xD;
          -  Prior radiation therapy within 30 days prior to enrollment&#xD;
&#xD;
          -  Major surgery within 30 days prior to enrollment&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanta Chawla, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanta Chawla, MD</last_name>
    <phone>949-788-6700</phone>
    <email>spi-gcf-104@sppirx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheyney Fermin</last_name>
    <email>spi-gcf-104@sppirx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ACRC/ Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yuma Regional Medical Center Cancer Center</name>
      <address>
        <city>Yuma</city>
        <state>Arizona</state>
        <zip>85364</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Oncology</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center, Inc.</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bond &amp; Steele Clinic, P.A.</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33881</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Health Youngstown</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>Early Stage Breast Cancer</keyword>
  <keyword>Long-acting Myeloid Growth Factor</keyword>
  <keyword>Docetaxel + Cyclophosphamide (TC) Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

